Accuray Q4 revenue falls as tariff concerns, geopolitical tensions weigh on demand

Accuray Incorporated

19/08/2026 22:24

Overview
Radiation therapy systems maker's fiscal Q4 revenue fell 21% yr/yr on lower product sales
Company posted net loss for Q4, reversing prior-year profit
Accuray saw over $20 mln in cost and margin improvements from transformation plan

Outlook
Accuray withholds FY27 revenue and adjusted EBITDA guidance amid geopolitical, trade, tariff and macro uncertainty
Accuray expects continued growth in service revenue and improved service margins in fiscal 2027
Strategic partnerships expected to play a larger role in expanding company capabilities

Result Drivers
PRODUCT REVENUE DECLINE - Co said lower product sales drove the 21% yr/yr revenue decrease in Q4, with demand in some regions affected by geopolitical developments and tariff uncertainty
SERVICE REVENUE GROWTH - Q4 service revenue rose 6% yr/yr, which co said reflects continued momentum in its recurring revenue business
COST AND MARGIN IMPROVEMENT - Co said its transformation plan delivered over $20 mln in cost and margin improvements in fiscal 2026, exceeding its original target

Company press release: ID:nPn8KdjGCa

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Miss
$100.92 mln
$105.30 mln (1 Analyst)
Q4 Loss Per Share
 
$0.02
 
Q4 Net Loss
 
$1.94 mln
 
Q4 Gross Profit
 
$35.08 mln
 
Q4 Income From Operations
 
$5.52 mln
 
Q4 Loss Per Basic Share
 
$0.02
 
Q4 Operating Expenses
 
$29.55 mln
 

Analyst Coverage
The one available analyst rating on the shares is "hold"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."
Wall Street's median 12-month price target for Accuray Incorporated is $0.35, about 11.1% above its August 18 closing price of $0.32

Reuters Recommended Reads
Aug 18 - Iridex Q2 revenue falls as retina sales decline
Aug 18 - GE HealthCare appoints William Grogan as CFO, replacing Jay Saccaro
Aug 17 - Cancer immunotherapy developer CEL-SCI's Q3 net loss unchanged

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)